North

The Prime objective of “North America Human Insulin Market” report is to provides an in-depth analysis of all market dynamics including drivers and restraints, and trends and opportunities. Important factors supporting growth across various is also provided. Using the industrial figures, the market finds growth figures between the forecast period from 2019 to 2024. In order to present an executive-level model of the market and its future perspectives, the report presents a clear segmentation based on different parameters. The factors that affect these segments are also discussed in detail in the report.

Request For Sample Copy of North America Human Insulin Market Report @ https://www.industryresearch.co/enquiry/request-sample/13999759

Top Key Players Are:

  • Novo Nordisk
  • Sanofi
  • Eli Lilly

    North America Human Insulin Market Report Covers the Top Regions:

    United States, Canada, Mexico, Germany, United Kingdom, France, Italy, Spain, China, Japan, India, Australia, South Korea, GCC, South Africa, Brazil, Argentina.

    Scope of North America Human Insulin Market:

    The North America human insulin market is segmented by product type (basal or long-acting insulin, bolus or fast-acting insulin, traditional human insulin, combination insulin, and biosimilar insulin) and geography.

    Have Any Query, Ask Our Industry Experts @ https://www.industryresearch.co/enquiry/pre-order-enquiry/13999759

    Key Market Trends: – The United States Dominates the Market

    Among the North American countries, the United States dominates around 95% of the total insulin market in the region. This is mainly due to the high diabetes prevalence in the country.
    The United States records the highest healthcare expenditure ly, and it also has the higher adoption of advanced therapeutics.
    The market size of the insulin market in 2017 was USD 10.6 billion, and the market is expected to record a CAGR of 5.5% during the forecast period (2019-2024).
    Lantus occupied the largest market share in 2017. However, the product is expected to decrease during the forecast period, due to similar insulin glargines present in the market, like Toujeo and Basaglar.
    Toujeo is the brand of Sanofi that is an upgraded version of Lantus and acts for more than 30 hours. Basaglar is the biosimilar of Lantus. However, the product was approved as a follow-on biologics in the United States.

    Increasing Pricing Pressure

    The United States is the primary market for all the insulin manufacturers, since the revenue from the country alone accounts to approximately more than 50%, ly.
    Pharmaceutical companies have increased the price of insulin drugs since the past few years, owing to increased US payer pressure.
    Due to the high prevalence of diabetes, the number of patients relying on insulin are growing, due to which there is a high demand for insulin production in volume.
    Insulin is manufactured through sophisticated r-DNA technology, due to which there are very few companies in the market that produce insulin.
    Thus, there is very high competition between these manufacturers who always strive to meet the patient needs. With deductibles far outpacing income, insulin has become unaffordable even for well-off US citizens.

    Report Highlights:

    • Market Dynamics – Drivers, Restraints, and Opportunities
    • Market Segmentation – Types, Applications, Regions, and Technology
    • Market Trends
    • Competitive Landscape
    • SWOT Analysis and Porter’s Five Forces Analysis

    Purchase North America Human Insulin Market Report @ https://www.industryresearch.co/purchase/13999759

    Price of Report: $ 4000 (SUL)

    Detailed TOC of North America Human Insulin Market Research Report 2019 – 2024:

    1 INTRODUCTION
    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study

    2 RESEARCH METHODOLOGY

    3 EXECUTIVE SUMMARY

    4 MARKET DYNAMICS
    4.1 Market Overview
    4.2 Drivers
    4.3 Restraints
    4.4 Porter’s Five Forces Analysis
    4.4.1 Bargaining Power of Suppliers
    4.4.2 Bargaining Power of Consumers
    4.4.3 Threat of New Entrants
    4.4.4 Threat of Substitute Products and Services
    4.4.5 Intensity of Competitive Rivalry

    5 MARKET SEGMENTATION
    5.1 By Drug
    5.1.1 Insulin (Value and Volume 2012-2024)
    5.1.1.1 Basal or Long-acting Insulin
    5.1.1.1.1 Lantus (Insulin Glargine)
    5.1.1.1.2 Levemir (Insulin Detemir)
    5.1.1.1.3 Toujeo (Insulin Glargine)
    5.1.1.1.4 Tresiba (Insulin Degludec)
    5.1.1.1.5 Basaglar (Insulin Glargine)
    5.1.1.2 Bolus or Fast-acting Insulin
    5.1.1.2.1 NovoRapid/Novolog (Insulin Aspart)
    5.1.1.2.2 Humalog (Insulin Lispro)
    5.1.1.2.3 Apidra (Insulin Glulisine)
    5.1.1.3 Traditional Human Insulin
    5.1.1.3.1 Novolin/Actrapid/Insulatard
    5.1.1.3.2 Humulin
    5.1.1.3.3 Insuman
    5.1.1.4 Combination Insulin
    5.1.1.4.1 NovoMix (Biphasic Insulin Aspart)
    5.1.1.4.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
    5.1.1.4.3 Xultophy (Insulin Degludec and Liraglutide)
    5.1.1.5 Biosimilar Insulin
    5.1.1.5.1 Insulin Glargine Biosimilars
    5.1.1.5.2 Human Insulin Biosimilars
    5.2 Geography
    5.2.1 North America
    5.2.1.1 United States (Value and Volume 2012-2024)
    5.2.1.1.1 Basal or Long-acting Insulin
    5.2.1.1.2 Bolus or Fast-acting Insulin
    5.2.1.1.3 Traditional Human Insulin
    5.2.1.1.4 Combination Insulin
    5.2.1.1.5 Biosimilar Insulin
    5.2.1.1.6 By Company (Novo Nordisk, Sanofi, Eli Lilly and others)
    5.2.1.2 Canada (Value and Volume 2012-2024)
    5.2.1.2.1 Basal or Long-acting Insulin
    5.2.1.2.2 Bolus or Fast-acting Insulin
    5.2.1.2.3 Traditional Human Insulin
    5.2.1.2.4 Combination Insulin
    5.2.1.2.5 Biosimilar Insulin
    5.2.1.2.6 By Company (Novo Nordisk, Sanofi, Eli Lilly and others)
    5.2.1.3 Rest of North America (Value and Volume 2012-2024)
    5.2.1.3.1 Basal or Long-acting Insulin
    5.2.1.3.2 Bolus or Fast-acting Insulin
    5.2.1.3.3 Traditional Human Insulin
    5.2.1.3.4 Combination Insulin
    5.2.1.3.5 Biosimilar Insulin
    5.2.1.3.6 By Company (Novo Nordisk, Sanofi, Eli Lilly and others)

    6 MARKET INDICATORS
    6.1 Type 1 Diabetes Population (2013-2024)
    6.2 Type 2 Diabetes Population (2013-2024)

    7 COMPETITIVE LANDSCAPE
    7.1 COMPANY PROFILES
    7.1.1 Novo Nordisk
    7.1.2 Sanofi
    7.1.3 Eli Lilly
    7.2 COMPANY SHARE ANALYSIS
    7.2.1 Novo Nordisk
    7.2.2 Sanofi
    7.2.3 Eli Lilly
    7.2.4 Others

    8 MARKET OPPORTUNITIES AND FUTURE TRENDS

    About Industry Research:

    Industry Research is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in-depth market research. We are one of the top report resellers in the market, dedicated to bringing you an ingenious concoction of data parameters.

    Contact Us:

    Name: Ajay More

    Organization: Industry Research

    Phone: +44 20 3239 8187 / +14242530807

    Email: [email protected]

    Our latest Report: e-Health Market 2019 Share, Growth, Size, Opportunities, Trends, Regional Overview, Leading Company Analysis, And Key Country Forecast to 2024

    Our latest Report: SD Cards Market 2019: Global Industry Current Trends, Top Companies, Application, Growth Factors, Development and Forecast to 2025 Research Report

  • Charles Bevers
    News Reporter